stockrowBiogen Inc.
BIIBHealthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) Return on equity
Biogen Inc.'s return on equity over the twelve months to 30 September 2026 was 1.87%, down 5.5 percentage points from fiscal 2025 (7.39%). Over the past ten years it has ranged from 7.39% (fiscal 2025) to 44.7% (fiscal 2019) — the current reading is the lowest in ten years. That is below the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 7.39% | (2.97) |
| FY2024 | 10.4% | 2.12 |
| FY2023 | 8.24% | (16.79) |
| FY2022 | 25.0% | 10.65 |
| FY2021 | 14.4% | (18.92) |
| FY2020 | 33.3% | (11.36) |
| FY2019 | 44.7% | 10.09 |
| FY2018 | 34.6% | 14.03 |
| FY2017 | 20.5% | (13.90) |
| FY2016 | 34.4% | (0.70) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 78.4% |
| NVO Novo Nordisk A/S compare | 58.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| GSK GSK PLC Sponsored ADR compare | 25.5% |
| AZN AstraZeneca PLC compare | 22.6% |
| PFE Pfizer Inc. compare | 4.42% |
| BIIB Biogen Inc. | 1.87% |
| SNY Sanofi compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −22.5% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement